Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 19/20 | 0.48 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.46 |
| ▸ | EED | O75530 | 11/20 | 0.44 |
| ▸ | SUZ12 | Q15022 | 11/20 | 0.44 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.44 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.44 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255104 | 0.82 | EZH2 (0.61) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL14740260 | 0.74 | EZH2 (0.58) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL30350393 | 0.73 | EZH2 (0.62) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL14917597 | 0.72 | EZH1 (0.64) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL10255914 | 0.72 | EZH2 (0.69) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL14816657 | 0.71 | EZH2 (0.60) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL27979801 | 0.70 | EZH2 (0.70) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL10255922 | 0.69 | EZH2 (0.88) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL12684168 | 0.69 | EZH2 (0.68) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL12684087 | 0.69 | EZH2 (0.68) | EZH2EZH1EEDSUZ12RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |